- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03254836
Sleep and Survival in Colorectal Cancer
Sleep-wake Rhythm in the Perioperative Period in Patients Admitted for Elective Radical Surgery for Colorectal Cancer: an Observational Prospective Cohort Study.
Objective The objective of the current trial is to investigate the effect of perioperative sleep and circadian rhythm on the natural course of survival among patient diagnosed with colorectal cancer. Concurrently, outcome measures like depression, fatigue, quality of life, and co-morbidity will be measured continuously in the short-, intermediate- and long-term period following diagnosis.
The a-priori hypothesis is that preoperative sleep and circadian disturbances is a prognostic marker of reduced overall survival. Likewise, preoperative sleep-wake disturbances at baseline are expected to result in overall universally reduced quality of life, increased depression and fatigue. Furthermore, development of sleep-wake disturbances in the postoperative period as compared to preoperative sleep-wake rhythm is expected to a prognostic marker of negative outcomes.
Target and study population The study population are all patients diagnosed with colorectal cancer in Region Zealand recruited consecutively from the trial initiation until study end each patient with an intended 5 year follow-up period. All available cases will be included in the trial.
Study design The study will be an observational prospective cohort study applying a longituditional repeated measure design.
Exposures and outcomes of interest The primary outcomes in the trial are sleep and circadian outcomes measured via actigraphy in the perioperative period.
Furthermore, cancer related survival and overall survival in the 5 year follow-up period is considered primary outcomes.
Secondary outcomes consist of consecutively measured depression, fatigue, quality of life, follow-up treatment and co-morbidity.
Exposure variables are primary related to the cancer, i.e. cancer stage, surgical treatment, oncological treatment, baseline co-morbidity and pharmacological treatment. Some of the secondary outcomes could be expected to serve as confounding or mediating factors.
Meaningful control for confounding will in the analysis phase be cancer stage and baseline sleep-wake rhythm status.
Sampling methods All available cases will be sought included in the trial. No formal sample size has been performed and continues inclusion into the trial will be performed during an 1,5 year period.
Statistical analyses The relationship between overall survival and baseline sleep-wake rhythm will be investigated using survival statistics and/or multivariate logistic regression.
Expected results The investigators expect to see a marked difference in overall survival among patients with sleep and circadian disturbances at baseline.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Zealand
-
Roskilde, Zealand, Denemarken, 4000
- Department of Surgery, Zealand University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Diagnosis of colorectal cancer as determined at the multi-disciplinary team conference.
- Admitted to elective radical surgery at the department of surgery at Zealand University Hospital
- Age above 18 years
- Informed consent
Exclusion Criteria:
- Non-ability to complete the study as assessed by the investigator
- Non-fluent in Danish.
- History of cognitive impairment (e.g. dementia)
- Paralysis or inability to answer study questioners electronically.
- Stadium 4 colonic adenocarcinoma with no surgical treatment options as determined at the multi-disciplinary conference.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Colorectal cancer undergoing elective surgery
All patients eligible for elective curative intended surgery for colonic adenocarcinoma at Zealand University Hospital. Patients will recieve treatment as per standard of care. |
Elective radical surgery for adenocarcinoma.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Actigraphy
Tijdsspanne: Approximately 1 week preoperatively to 2 weeks postoperatively
|
Assessment of activity using accelerometor - Sleep and circadian assesment.
|
Approximately 1 week preoperatively to 2 weeks postoperatively
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Major Depression Inventory
Tijdsspanne: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Assesment of depression
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Insomnia Severity Index
Tijdsspanne: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Subjective sleep assesment
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Quality of life assesment
Tijdsspanne: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
EORCT-QLQ-C30
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Quality of life assesment
Tijdsspanne: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
EORCT-QLQ-CR29
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Mortality
Tijdsspanne: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Co-morbidity
Tijdsspanne: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Drug prescription history (Drug name and dosage)
Tijdsspanne: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Follow-up cancer treatment (Adjuvant chemotherapy, timing and duration)
Tijdsspanne: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Michael T Madsen, M.D., Department of Surgery, Zealand University Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Gedragssymptomen
- Psychische aandoening
- Ziekten van het spijsverteringsstelsel
- Ziekten van het zenuwstelsel
- Neoplasmata
- Dyssomnieën
- Neoplasmata per site
- Neurologische manifestaties
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Colon Ziekten
- Darmziekten
- Beroepsziekten
- Intestinale neoplasmata
- Rectale ziekten
- Chronobiologische stoornissen
- Depressie
- Slaap-waakstoornissen
- Colorectale neoplasmata
- Slaapstoornissen, circadiaans ritme
Andere studie-ID-nummers
- MTM-V3
- SJ-600 (Andere identificatie: Region Zealand ethics Comittee)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Standard of care
-
Eskisehir Osmangazi UniversityNog niet aan het wervenAcute infectieuze diarree bij kinderen
-
ChinaNormActief, niet wervend
-
Lindenhofgruppe AGKlinik Hirslanden, Zurich; St. Claraspital AG; Insel Gruppe AG, University Hospital...Nog niet aan het wervenKanker | Psycho-oncologieZwitserland
-
Fu Jen Catholic University HospitalWervingChronische nierziekte (CKD) | CKD Stadium 1-3Taiwan
-
Lega Cancro TicinoWervingKanker | Psychische noodZwitserland
-
Fundacion DexeusNog niet aan het werven
-
ASST Fatebenefratelli SaccoNog niet aan het wervenTuberculose-infectie | Tuberculose-infectie, latentItalië
-
University of GlasgowWerving
-
Ma Fei,MDAanmelden op uitnodiging
-
Compedica IncProfessional Education and Research InstituteVoltooidDiabetische voetzweerVerenigde Staten, Canada